204 related articles for article (PubMed ID: 37311434)
41. Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations.
Ng AP; Adams R; Tiong IS; Seymour L; Talaulikar D; Palfreyman E; Enjeti A; Tate C
Pathology; 2024 Jun; 56(4):459-467. PubMed ID: 38580613
[TBL] [Abstract][Full Text] [Related]
42. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
Hughes CFM; Gallipoli P; Agarwal R
Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
[TBL] [Abstract][Full Text] [Related]
43. The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory.
Bruehl FK; Osman MM; Chen D; Dalland JC
J Hematop; 2023 Jun; 16(2):65-71. PubMed ID: 38175439
[TBL] [Abstract][Full Text] [Related]
44. [Predisposition and progression of myelodysplastic syndromes].
Makishima H
Rinsho Ketsueki; 2021; 62(4):278-288. PubMed ID: 33967153
[TBL] [Abstract][Full Text] [Related]
45. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.
Leguit RJ; Orazi A; Kucine N; Kvasnicka HM; Gianelli U; Arber DA; Porwit A; Ponzoni M
Virchows Arch; 2022 Oct; 481(4):621-646. PubMed ID: 35819517
[TBL] [Abstract][Full Text] [Related]
46. Hereditary myeloid malignancies.
Rafei H; DiNardo CD
Best Pract Res Clin Haematol; 2019 Jun; 32(2):163-176. PubMed ID: 31203998
[TBL] [Abstract][Full Text] [Related]
47. Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
Tawana K; Drazer MW; Churpek JE
Leukemia; 2018 Jul; 32(7):1482-1492. PubMed ID: 29483711
[TBL] [Abstract][Full Text] [Related]
48. Pediatric Myelodysplastic Syndromes.
Patel SS
Clin Lab Med; 2021 Sep; 41(3):517-528. PubMed ID: 34304779
[TBL] [Abstract][Full Text] [Related]
49. Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium.
Nakano TA; Lau BW; Dickerson KE; Wlodarski M; Pollard J; Shimamura A; Hofmann I; Sasa G; Elghetany T; Cada M; Dror Y; Ding H; Allen SW; Hanna R; Campbell K; Olson TS
Pediatr Blood Cancer; 2020 Oct; 67(10):e28652. PubMed ID: 32779892
[TBL] [Abstract][Full Text] [Related]
50. Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias).
Hasserjian RP; Kelley TW; Weinberg OK; Morgan EA; Fend F
Am J Clin Pathol; 2019 Aug; 152(3):302-321. PubMed ID: 31263893
[TBL] [Abstract][Full Text] [Related]
51. Practical considerations for diagnosis and management of patients and carriers.
Niemeyer CM; Mecucci C
Semin Hematol; 2017 Apr; 54(2):69-74. PubMed ID: 28637619
[TBL] [Abstract][Full Text] [Related]
52. Application of the International Consensus Classification and World Health Organization 5th edition classification to a series of myeloid neoplasms.
Chopra S; Bailey NG
Am J Clin Pathol; 2023 Dec; 160(6):566-570. PubMed ID: 37587830
[TBL] [Abstract][Full Text] [Related]
53. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
54. MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.
McReynolds LJ; Yang Y; Yuen Wong H; Tang J; Zhang Y; Mulé MP; Daub J; Palmer C; Foruraghi L; Liu Q; Zhu J; Wang W; West RR; Yohe ME; Hsu AP; Hickstein DD; Townsley DM; Holland SM; Calvo KR; Hourigan CS
Leuk Res; 2019 Jan; 76():70-75. PubMed ID: 30578959
[TBL] [Abstract][Full Text] [Related]
55. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Arber DA; Orazi A; Hasserjian R; Thiele J; Borowitz MJ; Le Beau MM; Bloomfield CD; Cazzola M; Vardiman JW
Blood; 2016 May; 127(20):2391-405. PubMed ID: 27069254
[TBL] [Abstract][Full Text] [Related]
56. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
[TBL] [Abstract][Full Text] [Related]
57. Pediatric Germline Predisposition to Myeloid Neoplasms.
Thompson C; Ariagno S; Kohorst MA
Curr Hematol Malig Rep; 2022 Dec; 17(6):266-274. PubMed ID: 36117229
[TBL] [Abstract][Full Text] [Related]
58. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract][Full Text] [Related]
59. Genetic predisposition to leukemia and other hematologic malignancies.
Feurstein S; Drazer MW; Godley LA
Semin Oncol; 2016 Oct; 43(5):598-608. PubMed ID: 27899193
[TBL] [Abstract][Full Text] [Related]
60. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
